UBS Initiates Coverage On HF Sinclair with Neutral Rating, Announces Price Target of $58
UBS analyst Manav Gupta initiates coverage on HF Sinclair (NYSE:DINO) with a Neutral rating and announces Price Target of $58.
UBS Initiates Coverage On Delek US Hldgs with Neutral Rating, Announces Price Target of $29
UBS analyst Manav Gupta initiates coverage on Delek US Hldgs (NYSE:DK) with a Neutral rating and announces Price Target of $29.
UBS Initiates Coverage On Valero Energy with Buy Rating, Announces Price Target of $176
UBS analyst Manav Gupta initiates coverage on Valero Energy (NYSE:VLO) with a Buy rating and announces Price Target of $176.
PI Financial Initiates Coverage On Lithium Americas with Buy Rating, Announces Price Target of C$40
PI Financial analyst Justin Stevens initiates coverage on Lithium Americas (TSX:LAC) with a Buy rating and announces Price Target of C$40.
William Blair Initiates Coverage On NAPCO Security Techs with Outperform Rating
William Blair analyst Matthew Pfau initiates coverage on NAPCO Security Techs (NASDAQ:NSSC) with a Outperform rating.
Needham Reinstates Buy on Solid Power, Announces $5 Price Target
Needham analyst Chris Pierce reinstates Solid Power (NASDAQ:SLDP) with a Buy and announces $5 price target.
JMP Securities Initiates Coverage On Lantheus Holdings with Market Outperform Rating, Announces Price Target of $120
JMP Securities analyst David Turkaly initiates coverage on Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform rating and announces Price Target of $120.
JP Morgan Initiates Coverage On Scorpio Tankers with Overweight Rating, Announces Price Target of $87
JP Morgan analyst Samuel Bland initiates coverage on Scorpio Tankers (NYSE:STNG) with a Overweight rating and announces Price Target of $87.
Cantor Fitzgerald Initiates Coverage On Karuna Therapeutics with Neutral Rating, Announces Price Target of $214
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Neutral rating and announces Price Target of $214.
Jefferies Initiates Coverage On Lexicon Pharmaceuticals with Hold Rating, Announces Price Target of $3
Jefferies analyst Andrew Tsai initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Hold rating and announces Price Target of $3.